Last reviewed · How we verify
Guanfacine extended-release tablets
Guanfacine extended-release tablets is a Small molecule drug developed by Children's Specialized Hospital. It is currently FDA-approved. Also known as: Intuniv (TM), guanfacine HCl, SPD503.
Guanfacine extended-release tablets, marketed by Children's Specialized Hospital, hold a niche position in the pharmaceutical market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market stability. The primary risk lies in the lack of disclosed revenue data and key trial results, which may limit investor confidence and competitive positioning.
At a glance
| Generic name | Guanfacine extended-release tablets |
|---|---|
| Also known as | Intuniv (TM), guanfacine HCl, SPD503 |
| Sponsor | Children's Specialized Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Guanfacine for Alcohol Use Disorder (AUD) (PHASE2)
- Guanfacine Extended-release for Adolescents With Cannabis Use (PHASE2)
- Noradrenergic Add-on Therapy With Guanfacine (PHASE3)
- An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD (NA)
- Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents (NA)
- Guanfacine in Children With Tic Disorders (PHASE4)
- Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE3)
- Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Guanfacine extended-release tablets CI brief — competitive landscape report
- Guanfacine extended-release tablets updates RSS · CI watch RSS
- Children's Specialized Hospital portfolio CI
Frequently asked questions about Guanfacine extended-release tablets
What is Guanfacine extended-release tablets?
Who makes Guanfacine extended-release tablets?
Is Guanfacine extended-release tablets also known as anything else?
What development phase is Guanfacine extended-release tablets in?
Related
- Manufacturer: Children's Specialized Hospital — full pipeline
- Also known as: Intuniv (TM), guanfacine HCl, SPD503
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing